AUTOANTIBODIES IN THE PATHOGENESIS OF RHEUMATOID ARTHRITIS: DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF RHEUMATOID FACTOR AND ANTI-CCP

Tolibova Jasmina Jo'rabekovna
Student of Samarkand State Medical University
tolibovajasmin15@gmail.com
Akbarova Munisa Sherzod qizi
Student of Samarkand State Medical University
akbarovamunesa@gmail.com
Amriyeva Marjona Azim qizi
Student of Samarkand State Medical University
marjonaamriyeva200@gmail.com
Mardonova Dildora Ilkhom qizi
Student of Samarkand State Medical University
dildoramardonova25@gmail.com

Abstract: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by symmetric erosive polyarthritis and, in most patients, the production of disease-specific autoantibodies. This narrative review synthesizes current evidence on the pathogenic role of rheumatoid factor (RF) and anti-citrullinated protein antibodies (anti-CCP, also termed ACPA) in RA, drawing on the 2010 ACR/EULAR classification criteria and the 2022 and 2025 EULAR recommendations for the management of RA. Contemporary evidence indicates that autoantibody production is not merely a diagnostic marker but an active driver of disease: gene-environment interactions, including the HLA-DRB1 shared epitope and cigarette smoking, promote peptidylarginine deiminase-mediated citrullination of self-proteins at mucosal surfaces, triggering a break in immune tolerance and the generation of high-affinity anti-CCP antibodies and RF years before the onset of clinically apparent synovitis. Once formed, these autoantibodies create immune complexes that activate complement and Fcγ receptors, drive synovial macrophage and fibroblast cytokine release, and, in the case of anti-CCP, bind directly to citrullinated vimentin on osteoclast precursors to stimulate bone resorption independent of inflammation. Anti-CCP offers substantially higher specificity than RF (approximately 95–98% versus 60–80%) at comparable sensitivity, and seropositivity — particularly double positivity for RF and anti-CCP — predicts a more erosive disease course, greater risk of extra-articular manifestations, and a treatment response profile that favors early, aggressive intervention. A mechanism-based understanding of RF and anti-CCP, combined with early classification and individualized, biomarker-informed treatment, is central to limiting irreversible joint damage and improving long-term outcomes, including within the healthcare system of Uzbekistan.

Keywords: Rheumatoid arthritis, rheumatoid factor, anti-citrullinated protein antibody, anti-CCP, citrullination, synovitis, pannus, osteoclast, treat-to-target.

Methods

This work was prepared as a narrative literature review. A literature search was conducted in September 2026 using PubMed, the ACR and EULAR publication databases, and the websites of major rheumatology societies, with the search terms "rheumatoid arthritis," "rheumatoid factor," "anti-CCP," "ACPA," "citrullination," and "EULAR recommendations," combined with filters for publication in English between 2016 and 2026. Priority was given to the 2025 EULAR recommendations for the management of rheumatoid arthritis, the 2010 ACR/EULAR classification criteria, systematic reviews, and peer-reviewed original research; narrative summaries from established clinical reference sources were included for foundational background. Case reports and articles without accessible full text were excluded. A total of twelve sources meeting these criteria were selected and synthesized for this review.

Introduction

Rheumatoid arthritis is a common, chronic autoimmune disease characterized by symmetric inflammatory polyarthritis that, if inadequately treated, leads to progressive cartilage destruction, bone erosion, and irreversible joint deformity. Autoantibody production is a defining immunological hallmark of RA: rheumatoid factor, first described more than seventy years ago, and anti-citrullinated protein antibodies, characterized more recently through the anti-CCP (cyclic citrullinated peptide) assay, together distinguish seropositive from seronegative disease and carry substantial diagnostic and prognostic weight.

Contemporary understanding positions autoantibody generation as an initiating pathogenic event rather than a passive epiphenomenon of joint inflammation. A well-documented preclinical phase — during which anti-CCP and RF circulate in asymptomatic individuals for a period that can extend to several years — precedes the first clinical signs of synovitis, reflecting an early, mucosally driven break in immune tolerance that is later amplified into destructive joint disease. This framework, sometimes described as a continuum from "pre-RA autoimmunity" to established arthritis, has directly informed treat-to-target strategies and the biomarker-guided treatment sequencing reflected in the most recent EULAR management recommendations.

The aim of this review is to summarize the pathogenic mechanisms underlying RF and anti-CCP autoantibody generation in rheumatoid arthritis, their contribution to synovial inflammation and joint destruction, and their diagnostic and prognostic value in clinical practice, with particular emphasis on updated international classification and management recommendations.

Understanding the pathogenic and clinical role of RF and anti-CCP is relevant across several areas of clinical practice, including:

- Rheumatology (diagnosis, classification, and risk stratification of early arthritis)
- Laboratory medicine / immunology (assay methodology and interpretation of RF and anti-CCP titers)

- Pulmonology (screening for RA-associated interstitial lung disease in anti-CCP-positive patients)
- Cardiology (assessment of accelerated atherosclerotic risk in seropositive RA)
- Orthopedics (planning for joint damage and surgical intervention in erosive disease)
- Primary care (recognition of early inflammatory arthritis and timely rheumatology referral)

Pathogenesis of Autoantibody Generation

The generation of RF and anti-CCP begins outside the joint, at mucosal surfaces, and results from an interaction between genetic susceptibility and environmental exposure. The strongest genetic risk factor is the HLA-DRB1 "shared epitope," a conserved amino acid sequence in the peptide-binding groove that preferentially presents citrullinated peptides to $CD4^+$ T cells; the PTPN22 risk variant further lowers the threshold for autoreactive lymphocyte activation. Cigarette smoking and periodontal pathogens, most notably Porphyromonas gingivalis, are the best-characterized environmental triggers.

These triggers converge on citrullination, a post-translational modification in which peptidylarginine deiminase (PAD) enzymes convert peptidyl-arginine residues to citrulline within proteins such as fibrinogen, vimentin, and α-enolase. Citrullination occurs physiologically during apoptosis and inflammation, but chronic citrullination at the lung and gingival mucosa generates a sustained supply of citrullinated neoepitopes. In genetically susceptible individuals, these neoepitopes are recognized as foreign by shared-epitope HLA-DRB1 molecules, driving $CD4^+$ T-cell help for autoreactive B cells and a consequent break in peripheral immune tolerance.

The resulting germinal center reaction produces affinity-matured, class-switched anti-CCP antibodies, which typically appear first, followed later by rheumatoid factor — itself an autoantibody directed against the Fc portion of IgG, including IgG bound within anti-CCP-containing immune complexes. Both autoantibody systems can be detected in serum for a substantial preclinical period before the first joint symptoms, defining a window of "pre-RA" autoimmunity. Progression to clinically apparent arthritis appears to require a second event — proposed triggers include a further inflammatory insult, mechanical joint stress, or intra-articular citrullination — that allows circulating immune complexes to localize to the synovium and initiate synovitis. This stepwise pathway from susceptibility to synovitis is illustrated in Figure 1.



Figure 1. The stepwise pathway of autoantibody-driven autoimmunity in rheumatoid arthritis: genetic susceptibility and environmental triggers drive mucosal protein citrullination, a break in immune tolerance, pre-clinical autoantibody production, and immune complex formation, culminating in the onset of synovitis.

Pathogenic Role of RF and Anti-CCP in Joint Damage

Once established, RF and anti-CCP are not passive markers of disease but active participants in a self-amplifying inflammatory loop that sustains synovitis and drives structural damage. Immune complexes formed by anti-CCP or RF bound to citrullinated or IgG antigens deposit within the synovium, where they fix complement via the classical pathway and engage Fcγ receptors on resident synovial macrophages, triggering their activation.

Activated macrophages and fibroblast-like synoviocytes release the principal pro-inflammatory cytokines of RA — tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 (IL-1) — which sustain synovial inflammation, promote synovial hyperplasia, and drive formation of the pannus: an invasive, locally destructive tissue that erodes articular cartilage and juxta-articular bone. In parallel, anti-CCP antibodies exert a further, complement-independent pathogenic effect: they bind directly to citrullinated vimentin expressed on the surface of osteoclast precursors, stimulating osteoclast differentiation and bone resorption even before overt synovitis is present, which helps explain the early, localized bone loss observed in anti-CCP-positive individuals.

The destructive process is further reinforced by neutrophil extracellular trap formation (NETosis) and synoviocyte death within the inflamed joint, both of which release fresh citrullinated autoantigens into the synovial microenvironment. These

autoantigens re-engage the autoantibody response, closing a self-perpetuating cycle in which each round of inflammation generates the substrate for the next. This reinforcing loop is depicted in Figure 2.



Figure 2. The self-amplifying RA autoantibody cycle: ACPA/RF-immune complexes activate complement and Fcγ receptors, driving cytokine release, synovial hyperplasia with pannus formation, direct osteoclast activation, and release of fresh citrullinated autoantigens that re-fuel autoantibody production.

The relative diagnostic characteristics of the two autoantibody systems, which underlie their complementary use in clinical practice, are summarized in Table 1.

Parameter	Rheumatoid Factor (RF)	Anti-CCP (ACPA)
Antigen recognized	Fc portion of IgG	Citrullinated peptides/proteins (fibrinogen, vimentin, α-enolase)
Sensitivity for RA	Approximately 60–80%	Approximately 70–80%
Specificity for RA	Approximately 60–80% (lower; positive in other	Approximately 95–98% (higher; more RA-specific)

Parameter	Rheumatoid Factor (RF)	Anti-CCP (ACPA)
	conditions)	
Appearance relative to symptom onset	May precede symptoms, often later than ACPA	Can precede clinical arthritis by several years ("pre-RA")
Positivity in other diseases	Sjögren syndrome, chronic infections, hepatitis C, healthy elderly	Rare; occasionally in early Sjögren syndrome or SLE
Role in 2010 ACR/EULAR classification	Serology domain; low-positive = 2 points, high-positive = 3 points	Serology domain; low-positive = 2 points, high-positive = 3 points

Diagnostic and Prognostic Significance

In clinical practice, RF and anti-CCP serve two distinct but complementary purposes: aiding diagnosis of early inflammatory arthritis and stratifying long-term prognosis. Anti-CCP offers substantially higher specificity for RA than RF at broadly comparable sensitivity, making it particularly valuable for distinguishing RA from other causes of polyarthritis and for identifying patients within the pre-clinical or very early window who will go on to develop classifiable disease. RF remains useful, particularly when measured together with anti-CCP, as combined seropositivity increases diagnostic confidence and both antibodies contribute independently to the serology domain of the 2010 ACR/EULAR classification criteria, in which a cumulative score of 6 or more (from joint involvement, serology, acute-phase reactants, and symptom duration) classifies a patient as having definite RA.

Beyond diagnosis, seropositivity — and particularly double positivity for RF and anti-CCP — is one of the most consistent predictors of an aggressive disease phenotype, informing both prognosis and treatment strategy at diagnosis. The principal prognostic associations of seropositivity across clinical domains are summarized in Table 2.

Clinical Domain	Prognostic Implication of RF / Anti-CCP Seropositivity
● Radiographic joint damage	Seropositive patients, especially double-positive (RF+/anti-CCP+), show faster and more extensive erosive damage on radiography
● Disease course	Anti-CCP positivity predicts a more persistent, less remitting disease course than seronegative RA

Clinical Domain	Prognostic Implication of RF / Anti-CCP Seropositivity
● Extra-articular manifestations	High-titer RF is linked to rheumatoid nodules, vasculitis, and Felty syndrome
● Pulmonary involvement	Anti-CCP positivity is associated with increased risk of RA-associated interstitial lung disease
● Cardiovascular risk	Seropositive RA carries a higher burden of accelerated atherosclerosis and cardiovascular events than seronegative disease
● Treatment response / strategy	Seropositivity favors early initiation of methotrexate and supports preferential use of rituximab (B-cell depletion) when a biologic is required

Classification and Modern Treatment Approaches

The 2010 ACR/EULAR classification criteria were developed specifically to identify RA at an earlier, potentially more treatable stage than the previous 1987 criteria, which relied heavily on late radiographic and clinical features. The current criteria assign weighted points across four domains — the number and site of involved joints, serologic status (RF and/or anti-CCP, with high-positive titers exceeding three times the upper limit of normal scoring higher than low-positive titers), elevation of acute-phase reactants (CRP or ESR), and symptom duration of six weeks or more — with a cumulative score of 6 out of a possible 10 required for classification as definite RA.

Reflecting the prognostic weight of seropositivity, the 2025 EULAR recommendations for the management of RA reaffirm a treat-to-target strategy initiated with methotrexate, ideally combined with short-term glucocorticoids, at diagnosis. If the response is insufficient after three to six months, a biologic disease-modifying antirheumatic drug (bDMARD) should be added, or a Janus kinase inhibitor (JAKi) considered after careful evaluation of cardiovascular, malignancy, and thromboembolic risk. If the first bDMARD or JAKi fails, switching to another agent from the same or a different class is recommended, and DMARDs may be cautiously tapered once sustained remission is achieved, since abrupt discontinuation frequently precipitates a flare.

Seropositive status, and particularly a high-titer double-positive profile, is increasingly used to inform this sequencing: because seropositive RA is more likely to progress to erosive, treatment-resistant disease, it supports earlier escalation to combination or biologic therapy. Rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, is mechanistically well suited to seropositive disease, as it targets the autoantibody-producing B-cell lineage directly, and clinical response to rituximab is

generally more pronounced in RF- and anti-CCP-positive patients than in seronegative RA.

Conclusion

Rheumatoid factor and anti-CCP are best understood not as inert diagnostic biomarkers but as active participants in the pathogenic cascade of rheumatoid arthritis, from an initial mucosal break in immune tolerance to sustained synovial inflammation and progressive joint destruction. Anti-CCP offers greater specificity and earlier detectability than RF, while the combination of both antibodies within the 2010 ACR/EULAR classification criteria improves early diagnostic accuracy, and their seropositivity — especially in combination — identifies patients at greatest risk of erosive, treatment-resistant disease.

Systematic classification using validated criteria and biomarker-informed application of treat-to-target management, as reflected in the 2025 EULAR recommendations, are essential to limiting irreversible joint damage. Continued integration of mechanism-based understanding of RF and anti-CCP into individualized, guideline-directed care holds the potential to reduce disease-related disability and improve long-term outcomes for patients with rheumatoid arthritis, including within the healthcare system of Uzbekistan.

References

[1] Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.

[2] Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026 (Online First).

[3] Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588.

[4] Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360-1372.

[5] Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38-46.

[6] Wegner N, Wait R, Sroka A, et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2662-2672.

[7] Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380-386.

[8] Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122(5):1791-1802.

[9] Sokolove J, Johnson DS, Lahey LJ, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(4):813-821.

[10] van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7(7):391-398.

[11] Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183-196.

[12] Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.